ZeClínics Aims to Triple Turnover in 2022 and to Open Offices in Boston

ZeClínics has set its sights on the United States. The Spanish company specializing in preclinical trials and efficacy testing of new compounds plans to open its first office on the American continent, specifically in the city of Boston, according to Davide D’Amico and Javier Terriente, founders of ZeClínics.

The company has been working in this country for three years with different companies and academic centers and had also considered the possibility of landing in San Francisco. This company offers preclinical trials and efficacy testing of new compounds to pharmaceutical, biotech, and academic groups with efficacy or toxicity research.

At the moment, the company has three different programs: ZeTox, ZeGenesis, and ZeEfficacy, aimed at extracting and interpreting data from toxicity assays, gene editing, and custom phenotyping.

Read more about ZeClínics and find other important business headlines with our companion app Born2Invest.

ZeClínics has been working for three years in the United States with different business groups and academic centers

Looking ahead to 2022, the company is preparing an artificial intelligence (AI) platform that collects and interprets data to identify potential therapeutic targets. To implement this novelty, the company plans to open a financing round of more than five million euros. Even so, before carrying out this move, the company prioritizes finding a strategic partner specialized in AI.

In 2021, ZeClinics has almost tripled turnover compared to the previous year, to $3 million (€2.7 million). Looking ahead to 2022, the company expects to continue the same growth.

90% of the company’s turnover comes from outside Spain and it has customers on all five continents. Apart from the United States, ZeClínics also intends to prioritize the Japanese market, where it already has a commercial partner. The company currently employs 39 workers, has its headquarters in Barcelona and a laboratory at the Germans Tries i Pujol Hospital (Badalona).

90% of the company’s turnover comes from outside Spain and it has customers on five continents

The company was founded in 2013 and in 2015 starred in the first crowdfunding campaign through the Capital Cell platform, where it managed to raise €100,000 from 64 different investors. Four years later, the Catalan company launched ZeCardio Therapeutics.

This company is dedicated to the development of new drugs to combat cardiovascular diseases and ended up carrying out a spin out of ZeClínics. The company is led by two of the same co-founders D’Amico and Terriente and is under the umbrella of ZeLife Enterprises, the holding company that also includes ZeClinics.

__

(Featured Image by usmc0491 via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.